Skip to main content
PMC home page
Gut logoLink to Gut
. 1991 Sep;32(Suppl):S12–S17. doi: 10.1136/gut.32.suppl.s12

Pathogenesis of ascites and hepatorenal syndrome.

S P Wilkinson 1, K P Moore 1, V Arroyo 1
PMCID: PMC1405222  PMID: 1833293

Full text

PDF
S12

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arroyo V., Bosch J., Mauri M., Viver J., Mas A., Rivera F., Rodes J. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest. 1979 Feb;9(1):69–73. doi: 10.1111/j.1365-2362.1979.tb01669.x. [DOI] [PubMed] [Google Scholar]
  2. Arroyo V., Planas R., Gaya J., Deulofeu R., Rimola A., Pérez-Ayuso R. M., Rivera F., Rodés J. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest. 1983 Jun;13(3):271–278. doi: 10.1111/j.1365-2362.1983.tb00100.x. [DOI] [PubMed] [Google Scholar]
  3. Bernardi M., Trevisani F., Santini C., De Palma R., Gasbarrini G. Aldosterone related blood volume expansion in cirrhosis before and during the early phase of ascites formation. Gut. 1983 Aug;24(8):761–766. doi: 10.1136/gut.24.8.761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bichet D., Szatalowicz V., Chaimovitz C., Schrier R. W. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 1982 Apr;96(4):413–417. doi: 10.7326/0003-4819-96-4-413. [DOI] [PubMed] [Google Scholar]
  5. Boyer T. D., Zia P., Reynolds T. B. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology. 1979 Aug;77(2):215–222. [PubMed] [Google Scholar]
  6. Coratelli P., Passavanti G., Munno I., Fumarola D., Amerio A. New trends in hepatorenal syndrome. Kidney Int Suppl. 1985 Dec;17:S143–S147. [PubMed] [Google Scholar]
  7. Eggert R. C. Spironolactone diuresis in patients with cirrhosis and ascites. Br Med J. 1970 Nov 14;4(5732):401–403. doi: 10.1136/bmj.4.5732.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Epstein M., Berk D. P., Hollenberg N. K., Adams D. F., Chalmers T. C., Abrams H. L., Merrill J. P. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med. 1970 Aug;49(2):175–185. doi: 10.1016/s0002-9343(70)80073-0. [DOI] [PubMed] [Google Scholar]
  9. Epstein M., Larios O., Johnson G. Effects of water immersion on plasma catecholamines in decompensated cirrhosis. Implications for deranged sodium and water homeostasis. Miner Electrolyte Metab. 1985;11(1):25–34. [PubMed] [Google Scholar]
  10. Fernandez-Seara J., Prieto J., Quiroga J., Zozaya J. M., Cobos M. A., Rodriguez-Eire J. L., Garcia-Plaza A., Leal J. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology. 1989 Nov;97(5):1304–1312. doi: 10.1016/0016-5085(89)91704-6. [DOI] [PubMed] [Google Scholar]
  11. Ginès P., Jiménez W., Arroyo V., Navasa M., López C., Titó L., Serra A., Bosch J., Sanz G., Rivera F. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology. 1988 May-Jun;8(3):636–642. doi: 10.1002/hep.1840080333. [DOI] [PubMed] [Google Scholar]
  12. Govindarajan S., Nast C. C., Smith W. L., Koyle M. A., Daskalopoulos G., Zipser R. D. Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome. Hepatology. 1987 Jul-Aug;7(4):654–659. doi: 10.1002/hep.1840070407. [DOI] [PubMed] [Google Scholar]
  13. HECKER R., SHERLOCK S. Electrolyte and circulatory changes in terminal liver failure. Lancet. 1956 Dec 1;271(6953):1121–1125. doi: 10.1016/s0140-6736(56)90149-0. [DOI] [PubMed] [Google Scholar]
  14. Huber M., Kästner S., Schölmerich J., Gerok W., Keppler D. Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome. Eur J Clin Invest. 1989 Feb;19(1):53–60. doi: 10.1111/j.1365-2362.1989.tb00195.x. [DOI] [PubMed] [Google Scholar]
  15. Laffi G., La Villa G., Pinzani M., Ciabattoni G., Patrignani P., Mannelli M., Cominelli F., Gentilini P. Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenterology. 1986 Feb;90(2):274–282. doi: 10.1016/0016-5085(86)90921-2. [DOI] [PubMed] [Google Scholar]
  16. Lebrec D., Kotelanski B., Cohn J. N. Splanchnic hemodynamic factors in cirrhosis with refractory ascites. J Lab Clin Med. 1979 Feb;93(2):301–309. [PubMed] [Google Scholar]
  17. Levy M. Sodium retention and ascites formation in dogs with experimental portal cirrhosis. Am J Physiol. 1977 Dec;233(6):F572–F585. doi: 10.1152/ajprenal.1977.233.6.F572. [DOI] [PubMed] [Google Scholar]
  18. MARSON F. G. Total adrenalectomy in hepatic cirrhosis with ascites. Lancet. 1954 Oct 23;267(6843):847–848. doi: 10.1016/s0140-6736(54)91936-4. [DOI] [PubMed] [Google Scholar]
  19. Moore K. P., Taylor G. W., Maltby N. H., Siegers D., Fuller R. W., Dollery C. T., Williams R. Increased production of cysteinyl leukotrienes in hepatorenal syndrome. J Hepatol. 1990 Sep;11(2):263–271. doi: 10.1016/0168-8278(90)90123-9. [DOI] [PubMed] [Google Scholar]
  20. Moore K., Ward P. S., Taylor G. W., Williams R. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology. 1991 Apr;100(4):1069–1077. doi: 10.1016/0016-5085(91)90284-r. [DOI] [PubMed] [Google Scholar]
  21. Morgan T. R., Imada T., Hollister A. S., Inagami T. Plasma human atrial natriuretic factor in cirrhosis and ascites with and without functional renal failure. Gastroenterology. 1988 Dec;95(6):1641–1647. doi: 10.1016/s0016-5085(88)80090-8. [DOI] [PubMed] [Google Scholar]
  22. Panos M. Z., Gove C., Firth J. D., Raine A. E., Ledingham J. G., Westaby D., Williams R. Impaired natriuretic response to atrial natriuretic peptide in the isolated kidney of rats with experimental cirrhosis. Clin Sci (Lond) 1990 Jul;79(1):67–71. doi: 10.1042/cs0790067. [DOI] [PubMed] [Google Scholar]
  23. Pinzani M., Laffi G., Meacci E., La Villa G., Cominelli F., Gentilini P. Intrarenal thromboxane A2 generation reduces the furosemide-induced sodium and water diuresis in cirrhosis with ascites. Gastroenterology. 1988 Oct;95(4):1081–1087. doi: 10.1016/0016-5085(88)90186-2. [DOI] [PubMed] [Google Scholar]
  24. Rimola A., Ginés P., Arroyo V., Camps J., Pérez-Ayuso R. M., Quintero E., Gaya J., Rivera F., Rodés J. Urinary excretion of 6-keto-prostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome). J Hepatol. 1986;3(1):111–117. doi: 10.1016/s0168-8278(86)80154-4. [DOI] [PubMed] [Google Scholar]
  25. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest. 1977 Nov;37(7):635–642. doi: 10.3109/00365517709100657. [DOI] [PubMed] [Google Scholar]
  26. Rolando N., Harvey F., Brahm J., Philpott-Howard J., Alexander G., Gimson A., Casewell M., Fagan E., Williams R. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology. 1990 Jan;11(1):49–53. doi: 10.1002/hep.1840110110. [DOI] [PubMed] [Google Scholar]
  27. Salerno F., Badalamenti S., Incerti P., Capozza L., Mainardi L. Renal response to atrial natriuretic peptide in patients with advanced liver cirrhosis. Hepatology. 1988 Jan-Feb;8(1):21–26. doi: 10.1002/hep.1840080106. [DOI] [PubMed] [Google Scholar]
  28. Schrier R. W., Arroyo V., Bernardi M., Epstein M., Henriksen J. H., Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988 Sep-Oct;8(5):1151–1157. doi: 10.1002/hep.1840080532. [DOI] [PubMed] [Google Scholar]
  29. Schroeder E. T., Shear L., Sancetta S. M., Gabuzda G. J. Renal failure in patients with cirrhosis of the liver. 3. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. Am J Med. 1967 Dec;43(6):887–896. doi: 10.1016/0002-9343(67)90247-1. [DOI] [PubMed] [Google Scholar]
  30. Solis-Herruzo J. A., Duran A., Favela V., Castellano G., Madrid J. L., Muñoz-Yagüe M. T., Morillas J. D., Estenoz J. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol. 1987 Oct;5(2):167–173. doi: 10.1016/s0168-8278(87)80569-x. [DOI] [PubMed] [Google Scholar]
  31. Tachiyama G., Sakon M., Kambayashi J., Iijima S., Tsujinaka T., Mori T. Endogenous endotoxemia in patients with liver cirrhosis--a quantitative analysis of endotoxin in portal and peripheral blood. Jpn J Surg. 1988 Jul;18(4):403–408. doi: 10.1007/BF02471464. [DOI] [PubMed] [Google Scholar]
  32. Wernze H., Spech H. J., Müller G. Studies on the activity of the renin-angiotensin-aldosterone system (RAAS) in patients with cirrhosis of the liver. Klin Wochenschr. 1978 Apr 15;56(8):389–397. doi: 10.1007/BF01477293. [DOI] [PubMed] [Google Scholar]
  33. Wilkinson S. P., Bernardi M., Smith I. K., Jowett T. P., Slater J. D., Williams R. Effect of beta adrenergic blocking drugs on the renin-aldosterone system, sodium excretion, and renal hemodynamics in cirrhosis with ascites. Gastroenterology. 1977 Oct;73(4 Pt 1):659–663. [PubMed] [Google Scholar]
  34. Wilkinson S. P., Jowett T. P., Slater J. D., Arroyo V., Moodie H., Williams R. Renal sodium retention in cirrhosis: relation to aldosterone and nephron site. Clin Sci (Lond) 1979 Feb;56(2):169–177. doi: 10.1042/cs0560169. [DOI] [PubMed] [Google Scholar]
  35. Wilkinson S. P., Moodie H., Stamatakis J. D., Kakkar V. V., Williams R. Endotoxaemia and renal failure in cirrhosis and obstructive jaundice. Br Med J. 1976 Dec 11;2(6049):1415–1418. doi: 10.1136/bmj.2.6049.1415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Zipser R. D., Hoefs J. C., Speckart P. F., Zia P. K., Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab. 1979 Jun;48(6):895–900. doi: 10.1210/jcem-48-6-895. [DOI] [PubMed] [Google Scholar]
  37. Zipser R. D., Radvan G. H., Kronborg I. J., Duke R., Little T. E. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology. 1983 Apr;84(4):697–703. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES